SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): December 3, 2008 (December 2, 2008)

Neuralstem, Inc.

(Exact name of registrant as specified in Charter)

Delaware		000-1357459		52-2007292
(State or other jurisdiction of incorporation or organization)		(Commission File No.)		(IRS Employee Identification No.)

9700 Great Seneca Highway, Rockville, Maryland 20850

(Address of Principal Executive Offices)

(Issuer Telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

On December 2, 2008, Neuralstem, Inc. (“Company”) issued a press release announcing a collaboration between the Company and China Medical University & Hospital of Taiwan. The purpose of the collaboration is to advance the development of the Company’s human spinal cord neural stem cell therapies with a focus on Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease). A copy of the press release is attached to this report as Exhibit 99.1.

The information contained in this Current Report on Form 8-K and the exhibits attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information or such exhibits be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth in or exhibits to this Form 8-K shall not be deemed an admission as to the materiality of any information in this report on Form 8-K.

Item 9.01 Financial Statement and Exhibits.

Exhibit Number		Description

99.1		Press Release Dated December 2, 2008

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.


	NEURALSTEM, INC

	By:	/s/ I. Richard Garr
		I. Richard Garr
		Chief Executive Officer

Dated: December 3, 2008

Company Contact:		Investor Relations:
Richard Garr, President	(301) 366-4960	Equity Communications
Media Contact: Planet Communications		Ira Weingarten	(805) 897-1880
Deanne Eagle	(917) 837-5866	Steve Chizzik	(908) 688-9111

For Release: December 2, 2008

NEURALSTEM COLLABORATES WITH HOSPITAL IN TAIWAN TO DEVELOP
ADDITIONAL ALS STEM CELL CLINICAL TRIALS

Rockville, MD, December 2, 2008—Neuralstem Inc. (NYSE Alternext US:CUR) announced today that it has entered into a collaboration with the China Medical University & Hospital of Taiwan, to advance development of Neuralstem’s human spinal cord neural stem cell therapies. The collaboration will focus on Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease) with Dr. Shinn-Zong Lin, MD, PhD as principle investigator.

“We are pleased to have established this collaboration in Taiwan,” said Richard Garr, Neuralstem President & CEO. “The goal is to qualify our existing cGMP spinal cord cells into a human trial program to treat ALS in Taiwan. We would expect the Taiwan trial to follow the U.S. trial by about 6 to 9 months. As we prepare to submit an IND to treat ALS with our stem cells in the U.S. this fall, we continue to look for strategic relationships in both Europe and Asia that will allow us to move the cells into humans. Taiwan is a substantial and important market in Asia, and China Medical University is the National leader in innovative neurological research and treatments. We are very pleased to be adding them as another partner as we build out our worldwide network of neurosurgical centers capable of conducting clinical trials, and ultimately delivering our cell therapies.”

About Neuralstem

Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia.

Major Central Nervous System diseases targeted by the Company with research programs currently underway include: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury and ALS. The company's cells have extended the life of rats with ALS (Lou Gehrig's disease) as reported the journal TRANSPLANTATION, in collaboration with Johns Hopkins University researchers, and also reversed paralysis in rats with Ischemic Spastic Paraplegia, as reported in NEUROSCIENCE on June 29, 2007, in collaboration with researchers at University of California San Diego. The Company expects to file its first IND (Investigational New Drug) application with the FDA for ALS in the fall.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward- looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10- KSB for the year ended December 31, 2007 and the quarterly report on form 10-Q for the period ended September 30, 2008.

# # #